Good morning :)
Place Order
Add to Watchlist

Jubilant Pharmova Ltd

JUBLPHARMA

Jubilant Pharmova Ltd

JUBLPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,443 cr, stock is ranked 535
High RiskStock is 4.25x as volatile as Nifty
458.700.00% (+0.00)
458.700.00% (+0.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,443 cr, stock is ranked 535
High RiskStock is 4.25x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹7,443 cr, stock is ranked 535
High RiskStock is 4.25x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-166.641.381.07%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
44.585.120.70%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.

Investor Presentation

View older 

May 29, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -3.48%, vs industry avg of 8.45%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 3.72% to 1.98%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue5,934.445,762.505,886.297,557.879,146.566,233.676,389.186,141.456,332.316,555.88
Raw Materialssubtract2,530.062,157.872,114.722,920.963,523.711,592.641,516.381,550.331,918.645,724.28
Power & Fuel Costsubtract393.04366.71333.66424.92466.38112.21105.79134.30166.71
Employee Costsubtract1,090.281,125.091,230.931,555.881,925.961,843.221,922.882,043.392,166.02
Selling & Administrative Expensessubtract510.55396.06471.69619.21826.54631.50583.30666.14653.89
Operating & Other expensessubtract714.62456.46365.15478.48909.45281.20594.95589.66657.04
Depreciation/Amortizationsubtract287.95346.74291.40415.05370.90339.84348.95381.70554.03551.78
Interest & Other Itemssubtract367.61371.35341.11284.28219.81199.71184.10145.49188.20234.29
Taxes & Other Itemssubtract98.08150.40161.99216.28329.35335.11296.96216.5188.7790.20
EPS-3.1521.3431.7135.8131.6448.9348.7625.98-3.83-2.80
DPS2.602.602.602.603.914.345.005.005.005.00
Payout ratio0.120.080.070.120.090.100.19-1.78

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2014

Annual Report Unavailable

Investor Presentation

Feb 6PDF
FY 2015

Annual Report Unavailable

FY 2016

Annual Report Unavailable

Investor Presentation

Oct 29PDF
FY 2017

Annual Report Unavailable

Investor Presentation

Sep 23PDF
FY 2018

Annual Report Unavailable

FY 2021

Annual report

PDF

Investor Presentation

Jun 18PDF
FY 2023

Annual report

PDF

Investor Presentation

May 29PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Jubilant Pharmova Ltd-122.051.381.07%
Sun Pharmaceutical Industries Ltd34.864.980.93%
Cipla Ltd35.054.140.70%
Dr Reddy's Laboratories Ltd21.264.120.70%

Price Comparison

Compare JUBLPHARMA with any stock or ETF
Compare JUBLPHARMA with any stock or ETF
JUBLPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.68%0.42%1.23%23.21%24.46%

Dec 2022

Mar 2023

Jun 2023

Sep 2023

Shareholding History

JunSepDec '22MarJunSep23.47%23.06%23.38%23.22%23.20%23.21%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Jubilant Pharmova Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Nippon India PHARMA FUND DIRECT PLAN GROWTH PLAN - GROWTH OPTION GROWTH

Growth
0.2769%0.37%-0.01%29/33 (-1)
NIPPON INDIA NIFTY SMALLCAP 250 INDEX FUND-DIRECT PLAN-GROWTH

Growth
0.0233%0.24%-0.02%200/278 (-4)
Motilal Oswal Nifty Smallcap 250 Index Fund Direct Growth

Growth
0.0146%0.24%-0.02%191/277 (-6)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

JUBLPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.70 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 10, 2023

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 10, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateMar 9, 2020

Interim
Interim | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Mar 9, 2020

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹4.50

Dividend/Share

4.50

Ex DateEx Date

Sep 12, 2019